biosimilars

News

Sandoz said today it intends to double net sales between 2025 and 2035, fuelled by an acceleration in biosimilar medicine development.

News

Sandoz is set to add up to 10 new biosimilar assets to its portfolio under a new collaboration deal with China’s Shanghai Henlius Biotech.

Patients

Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry.

News

Sandoz has reached a settlement in the US that, if approved, could lay to rest years of litigation over price-fixing of generic medicines.

R&D

Biosimilars can help support broader patient access while contributing to the long-term sustainability of healthcare systems.

Patients

Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.